89
Participants
Start Date
September 20, 2017
Primary Completion Date
October 12, 2018
Study Completion Date
November 8, 2018
VX-150
Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
Placebo
Participants received placebo matched to VX-150 for 6 weeks.
The Mount Sinai Hospital, New York
Columbia University Medical Center, New York
Albany Medical Center- Neurology Group, Albany
University of Rochester, Rochester
The Johns Hopkins Hospital, Baltimore
Carilion Clinic Neurology, Roanoke
Carolinas Pain Institute, Winston-Salem
University of North Carolina School of Medicine, Chapel Hill
Duke Neurological Disorders Clinic, Durham
Bioclinica Research - Orlando, Orlando
Infinity Clinical Research, Sunrise
Neurology Diagnostics, Inc, Dayton
University of Iowa Hospitals and Clinics, Iowa City
Southern Illinois University (SIU) School of Medicine, Springfield
Washington University School of Medicine in St. Louis, St Louis
University of Kansas Medical Center (KUMC), Kansas City
International Clinical Research Institute (ICRI), Overland Park
River Cities Clinical Research Center, Shreveport
The Richter Clinic for Neurology and Neuro-Psychiatry, Tulsa
Blue Sky Neurology, Englewood
Xenoscience Inc. - 21st Century Neurology, Phoenix
Phoenix Neurological Associates, Ltd., Phoenix
University of New Mexico Hospital, Albuquerque
University of California San Diego, La Jolla
SDS Clinical Trials, Inc., Orange
Neuropain Medical Center, Fresno
Stanford University School of Medicine, Redwood City
Sutter Health - Alta Bates Summit Medical Center - The Jordan Research & Education Institute, Berkeley
University of Washington, Seattle
Dartmouth-Hitchcock Medical Center (DHMC), Lebanon
Robert Wood Johnson Medical School, New Brunswick
Universitätsklinikum Würzburg, Würzburg
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan
Maastricht UMC+, Maastricht
Vertex Pharmaceuticals Incorporated
INDUSTRY